Neurogene Balance Sheet Health
Financial Health criteria checks 6/6
Neurogene has a total shareholder equity of $137.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $164.1M and $26.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$138.99m |
| Equity | US$137.41m |
| Total liabilities | US$26.71m |
| Total assets | US$164.12m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: NGNE's short term assets ($143.6M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: NGNE's short term assets ($143.6M) exceed its long term liabilities ($10.9M).
Debt to Equity History and Analysis
Debt Level: NGNE is debt free.
Reducing Debt: NGNE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NGNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NGNE has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 4.6% each year.